<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Olmesartan: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Olmesartan: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Olmesartan: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10061" href="/d/html/10061.html" rel="external">see "Olmesartan: Drug information"</a> and <a class="drug drug_patient" data-topicid="10922" href="/d/html/10922.html" rel="external">see "Olmesartan: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709179"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">When pregnancy is detected, discontinue olmesartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F203488"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Benicar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867753"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Olmesartan;</li>
<li>AG-Olmesartan [DSC];</li>
<li>APO-Olmesartan;</li>
<li>Auro-Olmesartan;</li>
<li>GLN-Olmesartan;</li>
<li>JAMP-Olmesartan;</li>
<li>NRA-Olmesartan;</li>
<li>Olmetec;</li>
<li>PMS-Olmesartan;</li>
<li>SANDOZ Olmesartan;</li>
<li>TEVA Olmesartan</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1028372"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Angiotensin II Receptor Blocker</span>;</li>
<li>
<span class="list-set-name">Antihypertensive Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F9944092"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consider lower starting dose in patients with possible depletion of intravascular volume (eg, patients receiving diuretics).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 5 years and ≥5 kg: Limited data available; efficacy results variable: Initial: 0.3 mg/kg/dose once daily; if initial response inadequate after 2 weeks, dose may be increased to 0.6 mg/kg/dose once daily. Dosing was evaluated in a double-blind, placebo-controlled study of 59 patients and some efficacy was demonstrated; however, results were not statistically significant.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 6 to 16 years:</p>
<p style="text-indent:-2em;margin-left:6em;">20 to &lt;35 kg: 10 mg once daily; if initial response inadequate after 2 weeks, dose may be increased; maximum daily dose: 20 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:6em;">≥35 kg: 20 mg once daily; if initial response inadequate after 2 weeks, dose may be increased; maximum daily dose: 40 mg/<b>day</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents &gt;16 years: Initial: 20 mg once daily; if initial response is inadequate, may be increased to 40 mg once daily after 2 weeks</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51131696"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, no initial dosage adjustment necessary; however, AUC is increased 3-fold in adult patients with CrCl &lt;20 mL/minute; dosing adjustment may be necessary, use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: There are no dosing recommendations provided in the manufacturer's labeling; has not been studied<b>.</b></p></div>
<div class="block dohp drugH1Div" id="F51131697"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, no initial dosage adjustment may be necessary; however, in adult patients with moderate hepatic impairment, an increase in AUC of ~60% was observed; use with caution.</p></div>
<div class="block doa drugH1Div" id="F203491"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10061" href="/d/html/10061.html" rel="external">see "Olmesartan: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used as an alternative in patients who cannot tolerate an ACE inhibitor (eg, due to cough) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-23247304','lexi-content-ref-Guyer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-23247304','lexi-content-ref-Guyer.1'])">Ref</a></span>). In patients with prior angiotensin-converting enzyme (ACE) inhibitor-associated angioedema (ie, without urticaria or other signs of hypersensitivity), an angiotensin II receptor blocker (ARB) may also be an alternative. ARBs do not appear to elevate the risk of angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30618189','lexi-content-ref-23147456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30618189','lexi-content-ref-23147456'])">Ref</a></span>); however, patients must be educated that angioedema due to an ACE inhibitor can sometimes reoccur within months following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21970934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21970934'])">Ref</a></span>); referral to an allergist may be appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-ST-elevation acute coronary syndrome (alternative agent) (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients should be hemodynamically stable before initiation. Use as a component of an appropriate medical regimen, which may also include antiplatelet agent(s), a beta-blocker, and a statin. Continue ARB therapy indefinitely for patients with concurrent diabetes, left ventricular ejection fraction ≤40%, hypertension, or stable chronic kidney disease (CKD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718'])">Ref</a></span>). Dosing is based on general dosing range in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 20 mg once daily; increase dose as tolerated up to 40 mg/day under close monitoring to avoid hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ST-elevation myocardial infarction (alternative agent) (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients should be hemodynamically stable before initiation. Use as a component of an appropriate medical regimen, which may also include antiplatelet agent(s), a beta-blocker, and a statin. Continue ARB therapy indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>). Dosing is based on general dosing range in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 20 mg once daily; increase dose as tolerated up to 40 mg/day under close monitoring to avoid hypotension.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use with another appropriate agent (eg, long-acting dihydropyridine calcium channel blocker or thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30354654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30354654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose (eg, increase the daily dose by doubling) as needed up to 40 mg once daily; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30354654','lexi-content-ref-Mann.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30354654','lexi-content-ref-Mann.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d8b6822-d348-4d03-bd66-4ea05b5dd0a9">Proteinuric chronic kidney disease, diabetic or nondiabetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuric chronic kidney disease, diabetic or nondiabetic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 20 mg once daily; titrate gradually (eg, by doubling the dose every 2 to 4 weeks) to the maximally tolerated dose, not to exceed 40 mg/day. <b></b>If proteinuria target is not met despite optimized dosage, consider additional therapies (eg, sodium-glucose cotransporter-2 inhibitor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-Perkovic.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-Perkovic.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991407"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥40 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;40 mL/minute: No initial dosage adjustment necessary. AUC is increased 3-fold in patients with CrCl &lt;20 mL/minute and a maximum dose of 20 mg/day has been recommended for these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11451213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11451213'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988626"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe: No initial dosage adjustment necessary. Total drug exposure increased ~60% in moderate impairment. Should be used with caution in patients with ascites due to cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-23463403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-23463403'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F203456"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (3%), headache (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (&gt;1%), hypertriglyceridemia (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (&gt;1%; may be severe and chronic)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (&gt;1%), increased creatine phosphokinase (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (&gt;1%), flu-like symptoms (&gt;1%), pharyngitis (&gt;1%), rhinitis (&gt;1%), sinusitis (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, acute renal failure, alopecia, anaphylaxis, angioedema, arthralgia, arthritis, asthenia, chest pain, dyspepsia, facial edema, gastroenteritis, hypercholesterolemia, hyperkalemia, hyperlipidemia, hyperuricemia, increased liver enzymes, increased serum bilirubin, increased serum creatinine, myalgia, nausea, peripheral edema, pruritus, rhabdomyolysis, skin rash, sprue-like symptoms, tachycardia, urticaria, vertigo, vomiting</p></div>
<div class="block coi drugH1Div" id="F203469"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use with aliskiren in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to olmesartan or any component of the formulation; concomitant use with aliskiren in patients with moderate to severe renal impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>); pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F203454"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Angiotensin II receptor antagonists (ARBs) do not appear to elevate the risk of angioedema (Rasmussen 2019; Toh 2012). Patients with a history of angioedema due to an angiotensin-converting enzyme (ACE) inhibitor must be educated that sometimes there can be recurrence within months following discontinuation (Beltrami 2011). No matter the cause of angioedema, prolonged frequent monitoring is required, especially if tongue, glottis, or larynx are involved, as they are associated with airway obstruction. Discontinue therapy immediately if angioedema occurs. Aggressive early management is critical. IM administration of epinephrine may be necessary. Do not readminister the ARB to patients who experience angioedema from this medication.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal effects: Symptoms of sprue-like enteropathy (ie, severe, chronic diarrhea with significant weight loss) has been reported; may develop months to years after treatment initiation with villous atrophy commonly found on intestinal biopsy. Once other etiologies have been excluded, discontinue treatment and consider other antihypertensive treatment. Clinical and histologic improvement was noted after treatment was discontinued in a case series of 22 patients (Ianiro 2014; Rubio-Tapia 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration; dose reduction may be considered. This transient hypotensive response is not a contraindication to further treatment with olmesartan.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic/Mitral stenosis: Use caution in patients with significant aortic/mitral stenosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ascites: Generally, avoid use in patients with ascites due to cirrhosis or refractory ascites; if use cannot be avoided in patients with ascites due to cirrhosis, monitor BP and renal function carefully to avoid rapid development of renal failure (AASLD [Runyon 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal artery stenosis: Use olmesartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution with preexisting renal insufficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Olmesartan has not been shown to be effective for hypertension in children &lt;6 years of age. Children &lt;1 year of age must not receive olmesartan for hypertension. The renin-angiotensin-aldosterone system plays a critical role in kidney development. Administering drugs that act directly on the renin-angiotensin-aldosterone system can have effects on the development of immature kidneys and alter normal renal development.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pregnancy: <b>[US Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected. </b></p>
<p style="text-indent:-2em;margin-left:4em;">• Race/Ethnicity: In Black patients, the BP-lowering effects of ARBs may be less pronounced. The exact mechanism is not known; differences in the renin-angiotensin-aldosterone system, low renin levels, and salt sensitivity more commonly found in Black patients may contribute (Brewster 2013; Helmer 2018; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: In patients on chronic ARB therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; however, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis 2011). Based on current research and clinical guidelines in patients undergoing noncardiac surgery, continuing ARBs is reasonable in the perioperative period. If ARBs are held before surgery, it is reasonable to restart postoperatively as soon as clinically feasible (ACC/AHA [Fleisher 2014]).</p></div>
<div class="block foc drugH1Div" id="F203464"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as medoxomil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Benicar: 5 mg, 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 20 mg, 40 mg</p></div>
<div class="block geq drugH1Div" id="F203451"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F203471"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Benicar Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $9.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $11.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $16.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Olmesartan Medoxomil Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $5.13 - $5.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $6.28 - $6.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $8.73 - $9.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867754"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as medoxomil: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Olmetec: 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 40 mg</p></div>
<div class="block exp drugH1Div" id="F9944094"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 2 mg/mL oral suspension may be made with olmesartan tablets. Combine 50 mL purified water and twenty 20 mg tablets in an 8-ounce amber bottle and allow to stand for ≥5 minutes. Shake well for ≥1 minute, then allow to stand for ≥1 minute. Repeat shaking and standing process four additional times. Add 100 mL Ora-Sweet® and 50 mL Ora-Plus® to the suspension and shake well for ≥1 minute. Label "shake well" and "refrigerate".  Stable for 28 days refrigerated.</p>
<div class="reference">Benicar® prescribing information, Daiichi Sankyo, Inc, Parsippany, NJ, 2010.</div>
</div>
<div class="block admp drugH1Div" id="F52613467"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered with or without food.</p></div>
<div class="block adm drugH1Div" id="F203466"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food.</p></div>
<div class="block sts drugH1Div" id="F203483"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53568090"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hypertension alone or in combination with other antihypertensive agents (FDA approved in ages 6 to 16 years and adults)</p></div>
<div class="block mst drugH1Div" id="F7914230"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Benicar may be confused with Mevacor</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9837691"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OATP1B1/1B3 (SLCO1B1/1B3)</p></div>
<div class="block dri drugH1Div" id="F203458"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II: Receptor Blockers may diminish the therapeutic effect of Angiotensin II.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors.  Management: Use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives when possible. Monitor blood pressure, renal function, and potassium if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colesevelam: May decrease the serum concentration of Olmesartan. Management: Administer olmesartan at least 4 hours prior to colesevelam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Initiate lithium at lower doses in patients receiving an angiotensin II receptor blocker (ARB). Consider lithium dose reductions in patients stable on lithium therapy who are initiating an ARB. Monitor lithium concentrations closely when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Angiotensin II Receptor Blockers. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May enhance the adverse/toxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May enhance the adverse/toxic effect of Angiotensin II Receptor Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308557"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Angiotensin II receptor blockers (ARBs) are fetotoxic. Transition patients prior to conception to an agent preferred for use during pregnancy unless treatment with an ARB is absolutely necessary (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p></div>
<div class="block pri drugH1Div" id="F203472"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Exposure to an angiotensin II receptor blocker (ARB) during the first trimester of pregnancy may be associated with an increased risk of fetal malformations (ACOG 2019; ESC [Regitz-Zagrosek 2018]). Following exposure during the second or third trimesters, drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal kidney function, may lead to fetal lung hypoplasia and skeletal malformations. Oligohydramnios may not appear until after an irreversible fetal injury has occurred. ARB use during pregnancy is also associated with anuria, hypotension, kidney failure, skull hypoplasia, and death in the fetus/neonate. Monitor infants exposed to an ARB in utero for hyperkalemia, hypotension, and oliguria. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Discontinue ARBs as soon as possible once pregnancy is detected. Agents other than an ARB are recommended for the treatment of chronic hypertension during pregnancy (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]). Closely monitor patients exposed to an ARB during pregnancy with serial ultrasounds.</p></div>
<div class="block mopp drugH1Div" id="F53568089"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">The following should be measured at baseline and periodically with therapy: Blood pressure, BUN, serum creatinine, renal function, serum electrolytes (particularly potassium)</p></div>
<div class="block pha drugH1Div" id="F203453"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As a selective and competitive, nonpeptide angiotensin II receptor antagonist, olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II; olmesartan interacts reversibly at the AT1 and AT2 receptors of many tissues and has slow dissociation kinetics; its affinity for the AT1 receptor is 12,500 times greater than the AT2 receptor. Angiotensin II receptor antagonists may induce a more complete inhibition of the renin-angiotensin system than ACE inhibitors, they do not affect the response to bradykinin, and are less likely to be associated with non-renin-angiotensin effects (eg, cough and angioedema). Olmesartan increases urinary flow rate and, in addition to being natriuretic and kaliuretic, increases excretion of chloride, magnesium, uric acid, calcium, and phosphate.</p></div>
<div class="block phk drugH1Div" id="F203468"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 17 L; does not cross the blood-brain barrier (animal studies)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 99%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Olmesartan medoxomil is hydrolyzed in the GI tract to active olmesartan. No further metabolism occurs.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 26%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: 13 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: All as unchanged drug: Feces (50% to 65%); urine (35% to 50%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clearance: 1.3 L/hour; similar data reported in children (1 to 16 years) when adjusted by body weight</p></div>
<div class="block phksp drugH1Div" id="F51154911"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC is approximately tripled when CrCl is &lt;20 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with moderate hepatic impairment, AUC increased by ~60%; C<sub>max</sub> was also increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC increased by 33%, and there is a 30% reduction in renal Cl.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: AUC and C<sub>max</sub> increased 10% to 15% in women.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: Antihypertensive effect was smaller in black patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539905"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Arbolt | Calenda | Olmac | Olmepress | Olmespec | Olmetec | Olmezest | Olsar | Oxami</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Elsartan | Olmec | Tensonit</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mencord | Olmeblo | Olmesartan 1a pharma | Olmesartan actavis | Olmesartan Genericon | Olmesartan krka | Olmesartan ratiopharm | Olmesartan sandoz | Olmesartan stada | Olmetec</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">APO Olmesartan | Olmertan | Olmesartan an | Olmesartan myl | Olmesartan sandoz | Olmetec | Pharmacor olmesartan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Abetis | Olmecar | Olmepres | Olmesan | Olmevas | Olmezest | Olpres | Olsart | Orbas | Presulock | Ransys | Sevitan | Tenicar | Xyotil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Belsar | Olmesartan ab | Olmesartan eg | Olmesartan krka | Olmesartan sandoz | Olmesartan teva | Olmetec</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Olmat | Olmetec</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Olmesta | Olsart | Tansidor | Tensar</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Asea | Benicar | Fluxocor | Hipoxomil | Holmes | Olmecor | Olmedix | Olmegran | Olmesartana medoxomila | Olmetec | Olmy | Olsar</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Olmesartan mepha | Olmesartan sandoz | Olmesartan spirig HC | Olmetec | Votum</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Olmat | Olmetec</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cardioplus | Carvas | Iltux | Olmecard | Olmepress | Olmesartan medoxomilo | Olmetec | Oltan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao tan | Lan sha | Ou mei li | Tian quan an kang</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Adlersartan | Iltux | Olmedoxtan | Olmeprex | Olmesartan | Olmetan | Olmetec | Scriptene | Starolmi</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Olmetec | Sarten</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Belsar | Olmecor | Olmesartan 1a pharma | Olmesartan abz | Olmesartan al | Olmesartan amarox | Olmesartan glenmark | Olmesartan heumann | Olmesartan hexal | Olmesartan medoxomil accord | Olmesartan medoxomil macleods | Olmesartan ratiopharm | Olmetec | Votum</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Benicar | Eukene | Iltux | Olarbi | Olmedos | Olmesar | Olmesartan calox | Olmetec</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cardioplus | Eukene | Iltux | Olmesartan mk | Olmetec</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Mesar | Olimestra | Olmesartan medoxomil accord</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Angiosartan | Erastapex | Lezberg | Normesar | Olmeborg | Olmesab</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Atolme | Ixia | Olmesartan alter | Olmesartan apotex | Olmesartan aurovitas | Olmesartan cinfa | Olmesartan combix | Olmesartan hibes | Olmesartan kern pharma | Olmesartan krka | Olmesartan mabo | Olmesartan mylan | Olmesartan normon | Olmesartan pensa pharma | Olmesartan premium pharma | Olmesartan qualigen | Olmesartan ratiopharm | Olmesartan sandoz | Olmesartan stada | Olmesartan tecnigen | Olmesartan tevagen | Olmesartan vir | Olmesartan viso farmaceutica | Olmetec | Openvas</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Olmat | Olvas</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Olmesartan medoxomil accord | Olmesartan medoxomil Krka | Olmesartan medoxomil sandoz | Olmesartan medoxomil stada | Olmetec</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Alteis | Olmetec</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Olmesartan | Olmetec</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ipertas | Olartan | Olmesartan medoxomil/teva | Olmesartan/mylan | Olmesartan/sandoz | Olmetec</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Esatec | Olmecar | Olmecor | Olmesartan | Olmetec</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Olmesartan Genericon</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Laresin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Olmetec</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Benetor | Olmesartan rowex | Omesar</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Olmetec</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alomesartan | Benitec | Hybreed | Normosart | O relate | Olarbi | Olcure | Olistar | Olkem | Olmark | Olmat | Olmax | Olmeblu | Olmecip | Olmedox | Olmeflex | Olmegraf | Olmesafe | Olmesar | Olmesat | Olmetime | Olmetor | Olmetrack | Olmezest | Olmighty | Olmin | Olmirest | Olmiryl | Olmy | Olright | Olsavas | Olsertain | Olvance | Olvas | Olways | Olzox | Omesvio | Ortan | Pinom | Rasotan | Xirtam | Zoltab</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Idalman | Olmedie | Olmesartan doc generici | Olmesartan eg | Olmesartan hcs | Olmesartan medoxomil accord | Olmesartan medoxomil alter | Olmesartan medoxomil aurobindo | Olmesartan medoxomil Pensa | Olmesartan medoxomil sandoz | Olmesartan medoxomil teva | Olmesartan medoxomil zentiva | Olmesartan provvisoria | Olmesartan tecnigen | Olmetec | Olpress | Plaunac</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Olvans | Votum</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Olmesartan amel | Olmesartan chemiphar | Olmesartan jg | Olmesartan kn | Olmesartan kyorin | Olmesartan nichiiko | Olmesartan nipro | Olmesartan nissin | Olmesartan ohara | Olmesartan sanwa | Olmesartan tck | Olmesartan tsuruhara | Olmesartan yd | Olmetec</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Olkem | Olmat | Olme | Olmesar | Olvance | Orion</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Arb s | Bellmetec | Biol | Cellmetec | Emetan | Eseuol | Etex olmesartan | Gemetec | Genuone olmesartan | Humetec | Huniz olmesartan medoxomi | Ilyangbio olmesartan medoxomil | Lowteck | Mesaol | Mesar | New orsartan | Newmesartan | Olbeca | Olcotan | Oldesar | Oldren | Olesartan | Oleten | Olgotan | Olle | Olme | Olme v | Olmeact | Olmec | Olmecan | Olmedil | Olmedin | Olmepam | Olmerin | Olmeron | Olmesan | Olmesar | Olmesartan | Olmesin | Olmestan | Olmetec | Olmetel | Olmexetil m | Olmezartan | Olmezatan | Olmezin | Olmos | Olpre | Olsan | Olsartan | Olsartec | Olsatan | Olsaten | Olstec | Oltamax | Oltan | Olten | Olwinner | Omertec | Ometan | Omexil | Omezotan | Ormertan | Ormetan | Prisartan | Sunmetec | Ultan | Umetec | Wemetan | Wymetan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Olmetec</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Olmetec | Votum</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Mesar | Olimestra | Olmesartan actavis | Osaver</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Belsar | Olmesartan eg | Olmetec</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mesar | Olimestra | Olmesartan krka | Olmesartan medoxomil accord | Osaver</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Olmetec</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Almetec | Hitentor | Iltux | Mitzoratta | Norsat | Olmesartan | Olmesartan medoxomilo | Openvas | Restelox | Zolmixfar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Olmetec</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Bexatan | Olvance</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Olmesartan medoxomil Glenmark | Olmetec</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Benetor | Olmesartan medoxomil accord | Olmesartan medoxomil Krka | Olmetec</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Cardioplus | Eukene | Iltux | Morass | Olmecard | Olmeheart | Olmepharm | Olmetec | Tazopronil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Alzor | Cresart | Olesta | Olmat | Olmesartan | Olmetec | Olmexl | Olmezar</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Baritec | Benicar | Beniscot | Olmeday | Olmekan | Olmis | Olmisan | Olra | Olzide | Omestran | Omsana | Oximil | Pacivan</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Revival</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Benicar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Olmesartan medoxomil tecnigen | Olmesartan medoxomilo Alter | Olmesartan medoxomilo Atolme | Olmesartan medoxomilo Aurobindo | Olmesartan medoxomilo Aurovitas | Olmesartan medoxomilo Ciclum | Olmesartan medoxomilo Farmoz | Olmesartan medoxomilo generis | Olmesartan medoxomilo Krka | Olmesartan medoxomilo Mylan | Olmesartan medoxomilo Pentafarma | Olmesartan medoxomilo Ratiopharm | Olmesartan Medoxomilo Sandoz | Olmesartan medoxomilo teva | Olmesartan medoxomilo toLife | Olmesartan medoxomilo zentiva | Olmetec | Olsar</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Caditar | Holmer | Iltux | Olmesartan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Calenda | Olmepress | Olmestan | Olmetec | Olmysar</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Olmetec</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cardosal | Olimestra</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Calenda | Normatec | Olcontro | Olmepress | Olmetec | Olsar</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Olmetec</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Tensiol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Olimestra | Tenzar</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Esatec | Olmetec</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Olmecard | Olmetec</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Hipersar | Improve | Olgen | Olmeday | Olmysar | Ometan | Oxap</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Eusartan | Olmesardin | Olmetec | Olmetero | Olsaa | Omesar</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cardosal | Olmesar</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Olmat | Olmy</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Olsar | Tensonit</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aresan | Benicar | Biocor | Dropten | Eukene | Iltux | Obenic | Olarbi | Olmesartan | Olmesartan medoxomilo</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Olmecor | Olvance</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Olmecor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21970934">
<a name="21970934"></a>Beltrami L, Zanichelli A, Zingale L, Vacchini R, Carugo S, Cicardi M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema.<i> J Hypertens</i>. 2011;29(11):2273-2277. doi:10.1097/HJH.0b013e32834b4b9b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/21970934/pubmed" id="21970934" target="_blank">21970934</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Benicar (olmesartan) [prescribing information]. South Plainfield, NJ: Cosette Pharmaceuticals Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23721258">
<a name="23721258"></a>Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. <i>BMC Med</i>. 2013;11:141. doi:10.1186/1741-7015-11-141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/23721258/pubmed" id="23721258" target="_blank">23721258</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. <i>Can J Diabetes</i>. 2013;35(suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.1">
<a name="Cattran.1"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. <i>JAMA</i>. 2003;289(19):2560-2571.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11937178">
<a name="11937178"></a>Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol. <i>Lancet</i>. 2002;359(9311):995-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/11937178/pubmed" id="11937178" target="_blank">11937178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21630188">
<a name="21630188"></a>Enzensberger C, Eskef K, Schwarze A, et al. Course and Outcome of Pregnancy After Maternal Exposure to Angiotensin-II-Receptor Blockers-Case Report and Review of the Literature. <i>Ultraschall Med</i>. 2012;33(5):493-496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/21630188/pubmed" id="21630188" target="_blank">21630188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15701766">
<a name="15701766"></a>Epstein BJ, Gums JG. Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations. <i>Ann Pharmacother</i>, 2005;39(3):470-480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/15701766/pubmed" id="15701766" target="_blank">15701766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085961">
<a name="25085961"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):e278-e333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/25085961/pubmed" id="25085961" target="_blank">25085961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Guyer.1">
<a name="Guyer.1"></a>Guyer AC, Banerji A. ACE inhibitor-induced angioedema. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 26, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21388309">
<a name="21388309"></a>Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. <i>N Engl J Med</i>. 2011;364(10):907-917.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/21388309/pubmed" id="21388309" target="_blank">21388309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20385971">
<a name="20385971"></a>Hazan L, Hernández Rodriguez OA, Bhorat AE, et al. A Double-Blind, Dose-Response Study of the Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescents With Hypertension. <i>Hypertension</i>. 2010;55(6):1323-1330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/20385971/pubmed" id="20385971" target="_blank">20385971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29808707">
<a name="29808707"></a>Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. <i>Ann Pharmacother</i>. 2018;52(11):1143-1151. doi:10.1177/1060028018779082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/29808707/pubmed" id="29808707" target="_blank">29808707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(23):2610-2642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21271514">
<a name="21271514"></a>Hünseler C, Paneitz A, Friedrich D, et al. Angiotensin II Receptor Blocker Induced Fetopathy: 7 Cases. <i>Klin Padiatr</i>. 2011;223(1):10-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/21271514/pubmed" id="21271514" target="_blank">21271514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24805127">
<a name="24805127"></a>Ianiro G, Bibbò S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: sprue-like enteropathy associated with olmesartan. <i>Aliment Pharmacol Ther</i>. 2014;40(1):16-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/24805127/pubmed" id="24805127" target="_blank">24805127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21993710">
<a name="21993710"></a>Imai E, Chan JCN, Ito S, et al. Effects of Olmesartan on Renal and Cardiovascular Outcomes in Type 2 Diabetes With Overt Nephropathy: A Multicentre, Randomized, Placebo-Controlled Study. <i>Diabetologia</i>. 2011;54(12):2978-2986.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/21993710/pubmed" id="21993710" target="_blank">21993710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267. doi:10.1161/CIR.0000000000000041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int.</i> 2021b;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018935">
<a name="25018935"></a>Kidney Disease: Improving Global Outcomes (KDIGO). Chapter 10: Immunoglobulin A nephropathy.<i> Kidney Int Suppl (2011).</i> 2012;2(2):209-217. doi:10.1038/kisup.2012.23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/25018935/pubmed" id="25018935" target="_blank">25018935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Inter, Suppl.</i> 2013;3(1):1-150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36272764">
<a name="36272764"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2022;102(suppl 5):S1-S127. doi:10.1016/j.kint.2022.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/36272764/pubmed" id="36272764" target="_blank">36272764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34556256">
<a name="34556256"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. <i>Kidney Int</i>. 2021a;100(suppl 4):S1-S276. doi:10.1016/j.kint.2021.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/34556256/pubmed" id="34556256" target="_blank">34556256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Bakris GL. Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 16, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2">
<a name="Mann.2"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. http://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi:10.1161/CIR.0000000000000029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Olmetec (olmesartan) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perkovic.1">
<a name="Perkovic.1"></a>Perkovic V. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14610160">
<a name="14610160"></a>Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>N Engl J Med</i>. 2003;349(20):1893-1906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/14610160/pubmed" id="14610160" target="_blank">14610160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30618189">
<a name="30618189"></a>Rasmussen ER, Pottegård A, Bygum A, von Buchwald C, Homøe P, Hallas J. Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors – a nationwide registry-based cohort study. <i>J Intern Med</i>. 2019;285(5):553-561. doi:10.1111/joim.12867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/30618189/pubmed" id="30618189" target="_blank">30618189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi:10.1016/j.jash.2015.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
<span class="doi">10.1016/j.jash.2015.03.002</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22728033">
<a name="22728033"></a>Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe Spruelike Enteropathy Associated With Olmesartan. <i>Mayo Clin Proc</i>. 2012;87(8):732-738. doi:10.1016/j.mayocp.2012.06.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/22728033/pubmed" id="22728033" target="_blank">22728033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20542468">
<a name="20542468"></a>Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials. <i>Lancet Oncol</i>. 2010;11(7):627-636.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/20542468/pubmed" id="20542468" target="_blank">20542468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i>. 2011;124(22):2458-2473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147456">
<a name="23147456"></a>Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. <i>Arch Intern Med</i>. 2012;172(20):1582-1589. doi:10.1001/2013.jamainternmed.34<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/23147456/pubmed" id="23147456" target="_blank">23147456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11451213">
<a name="11451213"></a>von Bergmann K, Laeis P, Püchler K, Sudhop T, Schwocho LR, Gonzalez L. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. <i>J Hypertens Suppl</i>. 2001;19(1):S33-S40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/11451213/pubmed" id="11451213" target="_blank">11451213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hyperten (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30354654">
<a name="30354654"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i>. 2018;138(17):e484-e594. doi:10.1161/CIR.0000000000000596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/olmesartan-pediatric-drug-information/abstract-text/30354654/pubmed" id="30354654" target="_blank">30354654</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16034 Version 402.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
